BBIO
BridgeBio Pharma, Inc.Healthcare · $14.9B market cap
Verdict
We can't put a fair value on BBIO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow BBIO
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
2 of the investors we track hold BBIO. In Q2 2026, 2 trimmed. Who we track
Viking Global Investors
Viking Global Investors · as of Q2 2026
$741.0M
9,949,219 shares
Polen Capital Management
Polen Capital Management · as of Q2 2026
$298K
4,002 shares
Moves in Q2 2026
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works